Effectiveness and Safety of Guizhi Fuling Wan (Keishibukuryogan) on Prostate Diseases: A Systematic Review and Meta-Analysis
Wang Y, Li H, Jiang Y, Kitano H, Hinata N, Ogawa-Ochiai K · Journal of Integrative and Complementary Medicine · 2025 October 13
DOI 10.1177/27683605251385894
Objective
To investigate the effectiveness and safety of Guizhi Fuling Wan (Keishibukuryogan) for prostate diseases, including chronic prostatitis and benign prostatic hyperplasia.
Conclusions
Guizhi Fuling Wan is effective and safe for benign prostatic hyperplasia and chronic prostatitis, alleviating symptoms and improving clinical scale scores.
Critical Appraisal
Published research can offer valuable insights, but a paper’s conclusions may go beyond what its results support. Critical appraisal examines the methods, findings and limitations to clarify what can reasonably be concluded—and what remains uncertain.
This article has not yet been critically appraised by the Research Hub.
Learn more about Critical Appraisal
Insights
Guizhi Fuling Wan significantly improved both the rate of effectiveness and safety measures in treating both chronic prostatitis and benign prostatic hyperplasia.
The methodology undertaken involved identifying randomized controlled trials from English, Chinese, Japanese, and Korean databases; the data were in search date ranging from the database inception to July 2024. Rev-Man 5.4.1 software was utilized in analyzing the data from twenty-three studies which were subsequently included in a meta-analysis; twelve studies focused on chronic prostatitis while eleven studies were about benign prostatic hyperplasia.
The results from the meta-analysis revealed that Guizhi Fuling Wan had notably superior ratings of effectiveness when compared to control groups in the treatment of benign prostatic hyperplasia and chronic prostatitis. Additionally, this compound significantly decreased International Prostate Symptom scores and National Institutes of Health Chronic Prostatitis Symptom Index scores. The effects also included a reduction in post-void residual urine, reduction in prostate volume, and an increase in maximum urinary flow rate. Therapeutic effects on prostate cancer were reported by a few studies and no serious side effects were identified.
